Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 10/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1488335 | 0.82 | CYP3A4 (0.53) | CYP3A4CYP2D6CYP2C9CYP2C19HIF1A | |
| SCHEMBL31037787 | 0.80 | CYP3A4 (0.53) | CYP3A4CYP2D6CYP2C9CYP2C19HIF1A | |
| SCHEMBL1488639 | 0.79 | CYP3A4 (0.50) | CYP3A4CYP2D6CYP2C9CYP2C19HIF1A | |
| SCHEMBL29573681 | 0.77 | CYP3A4 (0.50) | CYP3A4CYP2D6CYP2C9CYP2C19HIF1A | |
| SCHEMBL21582430 | 0.77 | CYP3A4 (0.50) | CYP3A4CYP2D6CYP2C9CYP2C19HIF1A | |
| SCHEMBL4556581 | 0.77 | OPRD1 (0.44) | CYP3A4CYP2D6CYP2C9CYP2C19HIF1A | |
| SCHEMBL71724 | 0.74 | NPSR1 (0.57) | CYP3A4CYP2D6CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL6206565 | 0.74 | CYP3A4 (0.52) | CYP3A4CYP2D6CYP2C9CYP2C19HIF1A | |
| SCHEMBL15416236 | 0.74 | CYP3A4 (0.52) | CYP3A4CYP2D6CYP2C9CYP2C19HIF1A | |
| SCHEMBL21582335 | 0.74 | CYP2D6 (0.46) | CYP3A4CYP2D6CYP2C9CYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024138112-A1 | INDAZOLE COMPOUNDS | TYRA BIOSCIENCES, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| CN-112979630-A | Trifluoromethanols as Ror gamma t modulators | 詹森药业有限公司 | 2021-06-18 | — | — | CN | disclosed |
| EP-3354651-B1 | TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-06 | — | — | EP | disclosed |
| EP-3212643-B1 | TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2019-03-20 | — | — | EP | disclosed |
| US-10150762-B2 | Trifluoromethyl alcohols as modulators of RORγt | JANSSEN PHARMACEUTICA, NV (BE) | 2018-12-11 | — | — | US | disclosed |
| EP-3354651-A1 | TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF ROR-GAMMA-T | Janssen Pharmaceutica N.V. (BE) | 2018-08-01 | — | — | EP | disclosed |
| US-9850236-B2 | Trifluoromethyl alcohols as modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-26 | — | — | US | disclosed |
| US-9850236-B2 | Trifluoromethyl alcohols as modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-26 | — | — | US | disclosed |
| US-9850236-B2 | Trifluoromethyl alcohols as modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-26 | — | — | US | disclosed |
| US-20170327492-A1 | TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-16 | — | — | US | disclosed |
| US-20110212940-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-7919519-B2 | 1-(4-(5-Phenylbenzofuran-2-yl)benzyl)azetidine-3-carboxylic acids; anticarcinogenic, antiinflammatory, antiarthritic, antidiabetic agents; transplant rejection, autoimmune diseases, lupus, multiple sclerosis, psoriasis, inflammatory bowel disease, Chron's disease | EPIX PHARMACEUTICALS INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919519-B2 | 1-(4-(5-Phenylbenzofuran-2-yl)benzyl)azetidine-3-carboxylic acids; anticarcinogenic, antiinflammatory, antiarthritic, antidiabetic agents; transplant rejection, autoimmune diseases, lupus, multiple sclerosis, psoriasis, inflammatory bowel disease, Chron's disease | EPIX PHARMACEUTICALS INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919519-B2 | 1-(4-(5-Phenylbenzofuran-2-yl)benzyl)azetidine-3-carboxylic acids; anticarcinogenic, antiinflammatory, antiarthritic, antidiabetic agents; transplant rejection, autoimmune diseases, lupus, multiple sclerosis, psoriasis, inflammatory bowel disease, Chron's disease | EPIX PHARMACEUTICALS INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7842685-B2 | S1P1 receptor agonists and use thereof | AMGEN INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100029611-A1 | S1P1 receptor agonists and use thereof | AMGEN INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20080027036-A1 | S1P receptor modulating compounds and use thereof | EPIX DELAWARE, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027036-A1 | S1P receptor modulating compounds and use thereof | EPIX DELAWARE, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027036-A1 | S1P receptor modulating compounds and use thereof | EPIX DELAWARE, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| WO-2007109334-A2 | SIP RECEPTOR MODULATING COMPOUNDS AND USE THEREOF | EPIX DELAWARE, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027036-A1 | S1P receptor modulating compounds and use thereof | S1PR1, S1PR5, S1PR2 | CYP3A4 2766/4885CYP2D6 3644/4885CYP2C9 3397/4885 |
| US-20100029611-A1 | S1P1 receptor agonists and use thereof | S1PR1, S1PR5, S1PR2 | CYP3A4 2976/4885CYP2D6 3405/4885CYP2C9 3802/4885 |
| US-20110212940-A1 | S1P Receptor Modulating Compounds and Use Thereof | S1PR1, S1PR5, S1PR2 | CYP3A4 2766/4885CYP2D6 3644/4885CYP2C9 3397/4885 |
| US-20170327492-A1 | TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt | RORA, RORC, RORB | CYP3A4 726/4885CYP2D6 1204/4885CYP2C9 3667/4885 |
| US-10150762-B2 | Trifluoromethyl alcohols as modulators of RORγt | RORC, RORA, RORB | CYP3A4 459/4885CYP2D6 916/4885CYP2C9 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.